SCHEMBL27211356

SCHEMBL27211356

COc1ncc(C2CCCN(C(=O)OC(C)(C)C)C2)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.51
PRMT5 O14744 1/20 0.49
PIK3CA P42336 1/20 0.49
PDE4B Q07343 1/20 0.48
HPGDS O60760 2/20 0.46
PROKR1 Q8TCW9 1/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
SSTR4 P31391 1/20 0.42
ALOX5AP P20292 1/20 0.42
FEN1 P39748 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25344277 1.00 PIK3CD (0.51) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL30473674 1.00 PIK3CD (0.51) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL27211334 0.88 PDE4B (0.47) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL29457556 0.88 PDE4B (0.47) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL27211151 0.88 PDE4B (0.47) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL25343640 0.88 PDE4B (0.47) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL25343649 0.88 PDE4B (0.47) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL25342400 0.88 PDE4B (0.47) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL27211190 0.88 PDE4B (0.47) PIK3CDPRMT5PIK3CAPDE4BHPGDS
SCHEMBL30473704 0.87 PRMT5 (0.46) PIK3CDPRMT5PIK3CAPDE4BHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976057-B2 MrgX2 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-05-07 US disclosed
CN-116390917-A MRGX2 antagonists 葛兰素史密斯克莱知识产权发展有限公司 2023-07-04 CN disclosed
WO-2022073904-A1 MRGX2 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-04-14 WO disclosed
US-20220112174-A1 MRGX2 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11976057-B2 MrgX2 antagonists MRGPRX2, MRGPRX1, MRGPRX4 PIK3CD 4261/4885PRMT5 907/4885PIK3CA 4494/4885
US-20220112174-A1 MRGX2 ANTAGONISTS MRGPRX2, MRGPRX1, MRGPRX4 PIK3CD 4261/4885PRMT5 907/4885PIK3CA 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.